Zim Laboratories Peer Comparison

NSE: ZIMLAB | BSE: 541400

₹136.86

₹2.34 (1.74%)

As on 09-Nov-2026IST

Market cap

₹738 Cr

Revenue (TTM)

₹414 Cr

P/E Ratio

356.2

P/B Ratio

2.5

Div. Yield

0 %

Edit

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	738	18,276	17,931	17,516	16,281
Revenue (₹ Cr)	414	1,842	2,654	3,330	2,602
Net Profit (₹ Cr)	2.07	308.62	859.38	720.77	177.73
Net Margin (%)	0.49	16.63	30.42	21.60	6.74
RoE (%)	0.70	11.81	18.58	18.93	21.49
Price to Earnings	356.21	54.98	20.86	24.76	91.60
Price-To-Book	2.52	6.63	4.09	4.23	18.52

Income Statement (₹ Cr)

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	413.56	1,841.62	2,654.29	3,329.63	2,602.07
Total Income	424.72	1,855.87	2,825.39	3,337.47	2,637.50
Total Expenditure	385.68	1,328.95	1,681.39	2,168.88	2,351.82
EBITDA	27.88	512.67	972.90	1,160.75	250.25
Depreciation	22.04	130.47	57.71	285.40	20.02
EBIT	5.84	382.20	915.19	875.35	230.23
Interest	14.32	49.12	8.91	187.51	6.94
Other Income	11.16	14.25	171.10	7.84	35.43
Exceptional Items	0.00	11.73	82.90	-53.14	-14.80
Profit before Tax	2.68	359.06	1,160.28	642.54	243.92
Provision for Tax	0.61	50.44	300.90	-78.23	66.19
Profit after Tax	2.07	308.62	859.38	720.77	177.73

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	292.39	2,757.68	4,385.41	4,144.34	878.92
Minority Interest	0.00	0.00	0.00	-10.85	0.00
Non-Current Liabilities	73.65	363.37	222.21	758.48	122.97
Current Liabilities	181.79	1,016.50	685.36	2,681.14	1,189.51
Total Liabilities	539.75	3,705.61	4,921.88	7,246.72	2,414.58

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	281.64	2,763.86	905.21	5,578.78	53.64
Current Assets	249.72	1,277.15	4,024.56	1,800.86	1,936.62
Total Assets	539.75	3,705.61	4,921.88	7,246.72	2,414.58
Total Debt*	122.82	657.97	2.50	2,309.68	0.00
Net Current Assets	67.93	260.65	3,339.20	-880.28	747.11
Contingent Liabilities	10.10	160.01	370.49	51.57	121.23

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	49.53	342.18	967.57	537.99	-15.14
Cash Flow from Investing Activities	-56.35	-325.92	-561.67	-369.46	18.69
Cash from Financing Activities	28.19	13.62	-798.31	-313.53	-91.97
Net Cash Inflow / Outflow	21.37	29.88	-392.41	-145.00	-88.42

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	5.47	11.43	23.39	14.47	31.24
ROE (%)	0.70	11.81	18.58	18.93	21.49
ROA (%)	0.41	8.09	17.36	9.78	9.34
EBIT Margin (%)	1.41	20.75	34.48	26.29	8.85
Net Margin (%)	0.49	16.63	30.42	21.60	6.74
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	13.14	37.26	11.75	11.06	29.70
EBIT Growth (%)	-63.86	56.89	21.45	13.71	-15.90
Net Profit Growth (%)	-68.56	127.86	2.39	60.98	-10.76
EPS Growth (%)	-65.29	5.65	13.17	80.38	-18.93
Book Value Growth (%)	17.07	9.67	-0.34	36.71	13.51

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	293.23	57.89	22.47	22.92	86.49
Price / Book Value	2.52	6.63	4.09	4.23	18.52
Dividend Yield (%)	0.00	0.06	1.91	0.00	0.55
EV/EBITDA	29.33	36.84	15.24	17.02	63.26
Market Cap (₹ Cr)	320.30	6,819.66	21,592.90	17,980.08	19,398.64

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.21	0.08	0.00	0.10	0.00
Short term debt to equity ratio	0.21	0.16	0.00	0.12	--
Current Ratio	1.37	1.26	5.87	0.67	1.63
Quick Ratio	0.91	0.82	5.23	0.49	0.76
Interest Coverage	1.19	8.31	131.22	4.43	36.15

	Zim Laboratories	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	24.53	29.09	9.10	18.98	10.95
Asset Turnover	0.81	0.48	0.54	0.45	1.37
Receivable days	105.27	113.81	26.06	63.88	31.88
Inventory Days	87.86	84.76	65.95	43.27	126.03
Payable days	157.18	101.94	81.01	151.85	163.79
Cash Conversion Cycle	35.94	96.62	11.00	-44.70	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.